¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor immunity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® epithelial tumor ÇÑ±Û »óÇǼºÁ¾¾ç
¼³¸í   
  Á¤»ó »ç¶÷ÀÇ Á¶Á÷Àº Ã¼Ç¥¸éÀ» µ¤´Â ¿ªÇÒÀ» Çϴ Á¶Á÷°ú, ÁַΠ¹ß»ý±âÀÇ Á߹迱¿¡¼­ ºÐÈ­ÇÑ °£¿±Á¶Á÷¿¡¼­ À¯·¡Çϴ °áÇÕÁ¶Á÷, »À, ¿¬°ñ, Áö¹æ, ±ÙÀ°, Ç÷°ü µîÀÇ Á¶Á÷ÀÇ µÎ °èÅëÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ÀüÀÚ¸¦ »óÇǼº Á¶Á÷, ÈÄÀÚ¸¦ ºñ»óÇǼº Á¶Á÷À̶ó Çϸ砱נ°¢°¢À» ±¸¼ºÇϴ ¼¼Æ÷¸¦ »óÇǼº ¼¼Æ÷, ºñ»óÇǼ¼Æ÷¶ó ÃÑĪÇÑ´Ù. »óÇǼº ¼¼Æ÷¿¡¼­ ±â¿øÇϴ Á¾¾çÀÌ »óÇǼº Á¾¾çÀ̸ç, ±ÙóÀÇ Á¶Á÷À¸·Î Ä§Åõ³ª Ç÷·ù, ¸²ÇÁÀÇ Á¶Á÷À» Å¸°í ¿ø°Å¸®ÀÇ Àå±â·Î À̵¿ÇÏÁö ¾Ê´Â ¾ç¼ºÁ¾¾ç¿¡´Â ¼±Á¾, À¯µÎÁ¾ µîÀÌ ÀÖ°í ¾ç¼º°ú ¹Ý´ë·Î ±ÙóÀÇ Á¶Á÷À¸·Î Ä§Åõ, ¿ø°ÝÀå±â·Î ÀüÀÌÇϴ ¾Ç¼ºÁ¾¾çÀ» ¸ðµÎ ÅëĪÇÏ¿© ¾ÏÁ¾(carcinoma)À̶ó°í ÇÑ´Ù.
¿µ¹® medullary tumor ÇÑ±Û ¼öÁú¼º Á¾¾ç
¼³¸í   
  ¾ÏÀÇ º´¸®ÇÐÀûÀΠºÐ·ùÁß Çϳª. ¿©·¯ ±â°üÀÇ ¾Ï¿¡¼­ ³ªÅ¸³ª´Âµ¥ ÁַΠ°©»ó»ù¾ÏÀ̳ª À¯¹æ¾Ï¿¡¼­ º¸ÀδÙ.
¿µ¹® malignant tumor ÇÑ±Û ¾Ç¼ºÁ¾¾ç
¼³¸í   
  Á¤»óÀûÀΠÁ¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀûÀΠ¹ß¾Ï ¹°ÁúÀÇ Àۿ렶Ǵ ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇϰԠÁõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀΠ°ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀΠ°ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
¿µ¹® benign tumor ÇÑ±Û ¾ç¼ºÁ¾¾ç
¼³¸í   
  ¹ßÀ°¼Óµµ°¡ ¿Ï¸¸ÇÏ¿© ¼ºÀå¿¡ ÇѰ谡 ÀÖ°í, ÁÖÀ§¿ÍÀÇ °æ°è°¡ ¸íÈ®Çϸç, ´Ù¸¥ Á¶Á÷À¸·Î ÆÛÁöÁö ¾ÊÀ¸¸ç, Ä§À±À̳ª ÀüÀ̸¦ ÀÏÀ¸Å°Áö ¾Æ´ÏÇϴ Á¾¾ç. ¼¶À¯Á¾À̳ª Áö¹æÁ¾ µûÀ§°¡ ÀüÇüÀûÀΠ¿¹ÀÌ´Ù. ¾ç¼ºÁ¾¾çÀº Á¾¾çÀÌ Á¸ÀçÇÑ´Ù°í Çصµ 1Â÷ÀûÀ¸·Î ¼÷ÁÖÀÇ »ý¸íÀ» À§ÇùÇϴ ÀÏÀº ¾ø´Ù. ¾ç¼ºÁ¾¾çÀÇ ¹ßÀ°Çü½ÄÀº ÁÖÀ§ÀÇ Á¶Á÷°£¿¡ ¿Õ·¡Çϴ ÀÏÀÌ ¾øÀÌ ÁÖÀ§ÀÇ Á¶Á÷À» ¹Ð¾î³»¸ç Áõ½ÄÇÑ´Ù. ¹ßÀ°¼Óµµ´Â ¿Ï¸¸Çϸç ÀüÀÌÇϰųª ÀýÁ¦ ÈÄ Àç¹ßÇϴ ÀÏÀÌ ±ØÈ÷ µå¹°´Ù. Á¾¾ç¼ººÐÀº º¯ÀÌüÀ̱ä ÇÏÁö¸¸ ¼º¼÷ÇÑ Á¤»ó¼¼Æ÷¿Í °ÅÀÇ ´Ù¸¥ °ÍÀÌ ¾ø´Ù. Àü½Å¿¡ ´ëÇÑ ¿µÇâÀº ¾Ç¼ºÁ¾¾çÀÇ °æ¿ì ¾î´À Á¤µµ ¹ßÀ°ÇßÀ» ¶§ Àü½ÅÀÇ ¿µ¾ç»óŰ¡ ¼Õ»óµÇ¾î Ä«Äʽþư¡ µÇÁö¸¸ ¾ç¼ºÁ¾¾çÀÇ °æ¿ì ÀÌ·± ÀÏÀº °ÅÀÇ ¾ø´Ù. ¾ç¼ºÁ¾¾ç°ú ¾Ç¼ºÁ¾¾çÀÇ ¼º»óÀÇ Â÷ÀÌ¿¡ ¾ö¹ÐÇÑ °æ°è´Â ¾ø°í, °æ°è°æº¯À¸·Î º¸À̴ Á¾¾çµµ ÀÖ´Ù.
¿µ¹® Wilms' tumor ÇÑ±Û Àª¸§ÁîÁ¾¾ç
¼³¸í   
  ÄáÆÏ¿¡¼­ ¹ß»ýÇϴ ¾Ç¼ºÁ¾¾çÀ¸·Î ¼Ò¾Æ¿¡¼­ ÀÚÁÖ ¹ß»ýÇÑ´Ù. ÈçÈ÷ ¼Ò¾Æ¿¡¼­ º¹ºÎ³»Á¾¾çÀ» ¹ß°ß½Ã Áß¾Ó¼±À» ³Ñ¾î¼­¸é ½Å°æ¸ð¼¼Æ÷Á¾À̰í, Áß¾Ó¼±À» ³ÑÁö ¾ÊÀ¸¸é Àª¸§ÁîÁ¾¾çÀ» ÀǽÉÇÒ ¸¸Å­ Áß¿äÇϰí ÈçÇÑ Á¾¾çÀÌ´Ù. ´ë°³ Áõ»óÀº ¾ø´Â ÆíÀ̸ç, ÁַΠ¾Æ±âÀÇ ¸ñ¿åÀ» ½ÃÄÑÁÖ´Ù°¡ ¿ì¿¬È÷ ¹ß°ßµÈ º¹ºÎ³»Á¾±« ¶§¹®¿¡ º´¿øÀ» Ã£°Ô µÈ´Ù. Áø´Ü½Ã ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µÀ¸·Î ÁÖÀ§ÀÇ ÀüÀ̰¡ ¾ø´ÂÁö¸¦ È®ÀÎÇØ¾ß Çϸç, ÀüÀ̰¡ ¾øÀ¸¸é Ç×¾ÏÈ­Çпä¹ý, ¹æ»ç¼±Ä¡·á¿ä¹ý, ±×¸®°í ¼ö¼ú¿ä¹ýÀÇ º´ÇÕ¿ä¹ý¿¡ ÀÇÇÑ Ä¡·áÈ¿°ú°¡ ³ô´Ù. 
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • individual immunity
    °³Àθ鿪, °³Ã¼¸é¿ª
  • infection immunity
    °¨¿°¸é¿ª
  • innate immunity
    ¼±Ãµ¸é¿ª
  • local immunity
    ±¹¼Ò¸é¿ª
  • maternal immunity
    ¸ð¼º¸é¿ª
  • nonspecific immunity
    ºñƯÀ̸鿪
  • native immunity
    °íÀ¯¸é¿ª
  • natural immunity
    ÀÚ¿¬¸é¿ª
  • opsonic immunity
    ¿É¼Ò´Ñ¸é¿ª
  • protective immunity
    ¹æ¾î¸é¿ª
  • passive immunity
    ¼öµ¿¸é¿ª
  • permanent immunity
    ¿µ±¸¸é¿ª
  • racial immunity
    ÀÎÁ¾¸é¿ª
  • relative immunity
    »ó´ë¸é¿ª
  • residual immunity
    ÀÜ¿©¸é¿ª
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • endodermal sinus tumor
    ³»¹è¿±±¼Á¾¾ç
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾
  • glomus tumor
    Å丮Á¾¾ç, »ç±¸Á¾¾ç
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
  • metastatic tumor
    ÀüÀÌÁ¾¾ç
  • neuroepithelial tumor
    ½Å°æ»óÇÇÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´ÉÁ¾¾ç
  • occult primary tumor
    Àẹ¿ø¹ßÁ¾¾ç
  • odontogenic tumor
    Ä¡¾ÆÅ¿Á¾¾ç, Ä¡¿øÁ¾¾ç
  • peripheral primitive neuroectodermal tumor
    ¸»ÃÊ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • phyllodes tumor
    ¿±»óÁ¾¾ç
  • primitive neuroectodermal tumor
    ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • impaired cellular immunity
    ¼¼Æ÷¸é¿ªºÎÀü
  • infection immunity
    °¨¿°¸é¿ª
  • innate immunity
    ¼±Ãµ¸é¿ª
  • local immunity
    ±¹¼Ò¸é¿ª
  • maternal immunity
    ¸ð¼º¸é¿ª
  • native immunity
    (¢¡innate immunity) ¼±Ãµ¸é¿ª
  • natural immunity
    ÀÚ¿¬¸é¿ª
  • nonspecific immunity
    ºñƯÀ̸鿪
  • opsonic immunity
    ¿É¼Ò´Ñ¸é¿ª
  • passive immunity
    ¼öµ¿¸é¿ª
  • permanent immunity
    ¿µ±¸¸é¿ª
  • protective immunity
    ¹æ¾î¸é¿ª
  • racial immunity
    ÀÎÁ¾¸é¿ª
  • relative immunity
    »ó´ë¸é¿ª
  • residual immunity
    ÀÜ¿©¸é¿ª
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • herd immunity
    Áý´Ü¸é¿ª, ±ºÁý¸é¿ª, ¹«¸®¸é¿ª
  • immunity, cross
    ±³Â÷¸é¿ª
  • immunity, gut
    Àå°ü¸é¿ª
  • immunity, herd
    Áý´Ü¸é¿ª, ±ºÁý¸é¿ª, ¹«¸®¸é¿ª
  • immunity, humoral
    ü¾×¼º¸é¿ª
  • immunity, innate
    ¼±Ãµ¸é¿ª
  • immunity, local
    ±¹¼Ò¸é¿ª
  • immunity, maternal
    ¸ð¼º¸é¿ª
  • immunity, native
    ¼±Ãµ¸é¿ª
  • immunity, nonspecific
    ºñƯÀ̸鿪
  • immunity, passive
    ¼öµ¿¸é¿ª
  • immunity, protective
    ¹æ¾î¸é¿ª
  • immunity, specific
    ƯÀ̸鿪
  • immunity, tissue
    Á¶Á÷¸é¿ª
  • immunity, transplantation
    À̽ĸ鿪
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º¸é¿ª(~Øóæ¹)
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª.
  • athreptic immunity
    ¹«¿µ¾ç¼º ¸é¿ª.
  • cell mediated immunity
    ¼¼Æ÷¼º¸é¿ª.
  • cell mediated immunity deficiency syndrome
    ¼¼Æ÷(¸Å°³)¸é¿ª°áÇÌÁõÈıº.
  • cell mediated immunity deficiency syndrome
    ¼¼Æ÷¼º¸é¿ª°áÇÌÁõÈıº.
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª(á¬øàØÚË¿Øóæ¹)
  • cell-mediated immunity(CMI)
    ¼¼Æ÷¸Å°³¼º ¸é¿ª
  • cellular immunity
    ¼¼Æ÷¸é¿ª
  • cellular immunity
    ¼¼Æ÷(¼º)¸é¿ª(¡­Øóæ¹).
  • combined immunity deficiency syndrome
    º¹Çո鿪°áÇÌÁõÈıº.
  • combined immunity deficiency synsdrome
    º¹Çո鿪°áÇÌÁõÈıº.
  • concomitant immunity
    ¼ö¹Ý¸é¿ª(¡­Øóæ¹).
  • concomitant immunity
    ¼ö¹Ý¸é¿ª(¡­Øóæ¹).
  • concomitant immunity
    ¼ö¹Ý¸é¿ª(¡­Øóæ¹).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cellular immunity
    ¼¼Æ÷¸é¿ª(á¬øàØóæ¹)
  • immunity
    ¸é¿ª(Øóæ¹)
  • inherited immunity
    À¯Àü¸é¿ª(ë¶îîØóæ¹)
  • innate immunity
    "ÀÚ¿¬¸é¿ª(í»æÔØóæ¹), ¼±Ãµ¸é¿ª(à»ô¸Øóæ¹)"
  • lysogenic immunity
    ¿ë¿ø¸é¿ª(éÁê«Øóæ¹)
  • native immunity
    ÀÚ¿¬¸é¿ª(í»æÔØóæ¹)
  • natural immunity
    ÀÚ¿¬¸é¿ª(í»æÔØóæ¹)
  • nonspecific immunity
    ºñƯÀÌ ¸é¿ª(Þª÷åì¶Øóæµ)
  • passive immunity
    ¼öµ¿¸é¿ª(áôÔÑØóæ¹)
  • protective immunity
    º¸È£ ¸é¿ª¼º(ÜÁûÞØóæ¹àõ)
  • specific immunity
    ƯÀ̸鿪(÷åì¶Øóæ¹)
  • superinfection immunity
    Áß°¨¿° ¸é¿ª (ñìÊïæøØóæ¹)
  • transferred immunity
    ÀüÀÌ ¸é¿ª (ï®ì¹Øóæ¹)
  • transplantation immunity
    ÀÌ½Ä ¸é¿ª(ì¹ãÕØóæ¹)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mucoepidermoid tumor
    Á¡¾×Ç¥ÇǾçÁ¾¾ç
  • mucous tumor
    Á¡¾×Á¾
  • nasopharyngeal tumor
    ºñÀεÎÁ¾¾ç
  • neurogenic tumor
    ½Å°æ(¿ø)¼ºÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´É¼ºÁ¾¾ç
  • odontogenic tumor
    Ä¡(¿ø)¼ºÁ¾¾ç
  • ovarian tumor
    ³­¼ÒÁ¾¾ç
  • papillary tumor
    À¯µÎ»ó Á¾¾ç
  • phantom tumor
    ȯ»óÁ¾¾ç
  • primary tumor
    ¿ù¹ßÁ¾¾ç
  • solid tumor
    Ãæ½Ç¼ºÁ¾¾ç
  • superior sulcus tumor
    »ó±¸Á¾¾ç
  • supratentorial tumor
    õ¸·»óÁ¾¾ç
  • teratodermoid tumor
    ±âÇüÀ¯ÇÇÁ¾
  • teratoid tumor
    ±âÇü¾çÁ¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CI cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar...
CIDS cellular immunity deficiency syndrome; circular intensity differential scattering; continuous insuli...
CMI carbohydrate metabolism index; care management integration; case mix index; cell-mediated immunity; ...
HI half-scan with interpolation; head injury; health insurance; hearing impaired; heart infusion; hemag...
immun immune, immunity, immunization
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BTA Bladder tumor antigen
TNF Cachectin/tumor necrosis factor
CEOT Calcifying epithelial odontogenic tumor
CBT carotid body tumor
CTR Connecticut Tumor Registry
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • natural active immunity
    ÀÚ¿¬ ´Éµ¿ ¸é¿ª
  • natural immunity
    ÀÚ¿¬ ¸é¿ª
  • phagocytic immunity
    ½Ä¼¼Æ÷¼º ¸é¿ª
  • racial immunity
    ¹ÎÁ· ¸é¿ª
    À¯ÀüÀûÀ¸·Î °áÁ¤µÇ¾î ÀÖ´Â ÀúÇ×¼ºÀ¸·Î, ¾î¶² Á¾Á· ¸ðµÎ ¶Ç´Â °ÅÀÇ ÀüºÎ°¡ ¾î¶² Á¾·ùÀÇ °£¿°¿¡ ´ëÇÏ¿© ³ªÅ¸³ª´Â ¸é¿ª »óÅÂ.
  • specific humoral immunity
    ƯÀ̼º ü¾× ¸é¿ª
  • transplantation immunity
    ÀÌ½Ä ¸é¿ª
  • acoustic tumor
    û½Å°æ Á¾¾ç
    Á¦ 8 ½Å°æ¿¡¼­ »ý±ä ¾ç¼º Á¾¾ç.
  • ACTH-secreting tumor
    ACTH-ºÐºñ Á¾¾ç
    µ¿ÀǾî=corticotro
  • adenomatoid tumor
    ¼± Á¾¾ç Á¾¾ç, À¯¼±Á¾ Á¾¾ç
    ¼ºÀå ¼Óµµ°¡ ´À¸° ÀÛÀº °áÀýÇüÀÇ ¾ç¼º Á¾¾çÀ̳ª ¶§·Î´Â ¼ö cm±îÁö µÉ ¼ö ÀÖ´Ù. ÀÌ Á¾¾çÀº ºÎ°íȯ Á¾¾ç Áß °¡Àå ÈçÇÏ¸ç ¿©ÀÚ¿¡¼­µµ Àڱà ¶Ç´Â ¼ö¶õ°üÀÇ À帷Ãþ¿¡ ¹ß»ýÇÒ ¼ö ÀÖ´Ù.
  • adrenal cortex tumor
    ºÎ½Å ÇÇÁú Á¾¾ç
  • amelanotic tumor
    ¹«¸á¶ó´Ñ Á¾¾ç
  • benign giant cell tumor
    ¾ç¼º °Å´ë¼¼Æ÷ Á¾¾ç
    1. °ñÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. °ñÀÇ ¾ç¼º Á¾¾çÀÇ Çϳª·Î ³ë¾àÀÚ¿¡°Ô ¸¹À¸¸ç ¹ß»ý ºÎÀ§´Â Àå°ü°ñÀÇ °ñ´Ü¿¡ ¸¹ÀÌ ³ªÅ¸³­´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¿øÇü, ¹æÃßÇüÀÌ ÀÖ´Ù. ¼¼Æ÷ »çÀÌ¿¡ ÆÄ°ñ¼¼Æ÷¿Í À¯»çÇÑ °Å´ë¼¼Æ÷°¡ È¥ÀçÇÑ´Ù. 2. °ÇÃÊÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. º»·¡ Á¾¾çÀÌ ¾Æ´Ï¸ç, °áÁ¤¼º °ÇÃÊ¿°À» °¡¸®Å°¸ç °ÇÃÊÀÇ ¼¶À¯¼º Á¶Á÷±¸Á¾¿¡ Æ÷ÇԵȴÙ.
  • benign melanocytic tumor
    ¾ç¼º ¸á¶ó´Ñ ¼¼Æ÷Á¾
  • benign vascular tumor
    ¾ç¼º Ç÷°üÁ¾
  • beta cell tumor
    º£Å¸ ¼¼Æ÷Á¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
cell-mediated immunity <immunology> Immune response that involves effector T lymphocytes and not the production of humoral antibody.
Responsible for allograft rejection, delayed hypersensitivity and in defence against viral infection and intracellular protozoan parasites.
(26 Mar 1998)
cellular immunity <cell biology, immunology> Immune response that involves enhanced activity by phagocytic cells and does not imply lymphocyte involvement. Since the term is easily confused with cell-mediated immunity its use in this sense should be avoided.
(26 Mar 1998)
cellular immunity deficiency syndrome <syndrome> A syndrome marked by increased susceptibility to infection, especially to viral infection, associated with defective functioning of the mechanism responsible for acquired immunity of the cell-mediated kind.
See: immunodeficiency.
(05 Mar 2000)
group immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
concomitant immunity The paradoxical immune status in which resistance to reinfection coincides with the persistence of the original infection.
Synonym: concomitant immunity.
(05 Mar 2000)
herd immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
humoral immunity <immunology> A form of immunity whereby B lymphocytes and plasma cells produce antibodies to foreign agents (antigens) and stimulate T lymphocytes to attack them (cellular immunity).
These antibodies also stimulate the release of chemical mediators (for example interferon, complement) which enhance antigen destruction.
(06 Mar 1998)
specific active immunity See: acquired immunity.
(05 Mar 2000)
specific immunity The immune status in which there is an altered reactivity directed solely against the antigenic determinants (infectious agent or other) that stimulated it.
See: acquired immunity.
(05 Mar 2000)
specific passive immunity See: acquired immunity.
(05 Mar 2000)
natural immunity This includes local barriers to infection such as skin, stomach acid, mucous, the cough reflex, enzymes in tears and saliva and skin oils.
(27 Sep 1997)
natural passive immunity Immunity conferred by the mother on the foetus or newborn.
(14 Nov 1997)
stress immunity Insusceptibility or resistance to the effects of emotional strain.
(05 Mar 2000)
immunity <immunology> The condition of being immune, the protection against infectious disease conferred either by the immune response generated by immunisation or previous infection or by other nonimmunologic factors.
Origin: L. Immunitas
(13 Oct 1997)
immunity, active Resistance to a disease agent resulting from the production of specific antibodies by the host, either after exposure to the disease or after vaccination.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á